Bill Meury joined Incyte in 2025 as President, Chief Executive Officer (CEO) and a member of the Company’s Board of Directors. With over three decades of industry experience, Mr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation.

Prior to joining Incyte, Mr. Meury was CEO of Anthos, where he successfully scaled the company for its next stage of growth. Before joining Anthos Therapeutics, Mr. Meury served as President and CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Prior to Karuna, he served as a Partner at Hildred Capital Management, a private equity firm focusing on healthcare products and services.

Earlier in his career, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas. He also served as Allergan’s President, Branded Pharma and Executive Vice President, Commercial, North American Brands, and as Executive Vice President Commercial Operations at Forest Laboratories prior to its acquisition by Allergan.

Mr. Meury has experience across a broad range of therapeutics areas and has been involved with over 20 U.S. FDA approvals and new product launches, as well as 25 different BD&L transactions.

He received his Bachelor of Arts degree in Economics from the University of Maryland and currently serves on the board of The Jed Foundation.